| |
| |
 |
| |
|
|
| |
April 16, 2002 |
|
| |
|
|
| |
– Plexxikon, Inc., a privately held drug discovery company, today announced that it has named John Kuriyan, PhD, to its Scientific Advisory Board. Dr. Kuriyan is the latest addition to a Board that includes several leading experts in the fields of protein crystallography, computational crystallography, chemistry, cell signaling, biochemistry and bioinformatics.
Dr. Kuriyan, an expert in the structural biology of cellular signal transduction and DNA replication, is an investigator at Howard Hughes Medical Institute, and chancellor's professor in the department of molecular and cell biology, and department of chemistry at the University of California, Berkeley.
Other members of Plexxikon's Scientific Advisory Board include:
Chairman - Sung-Hou Kim, PhD
Co-founder of Plexxikon and Professor, Department of Chemistry, the University of California, Berkeley, and head of the Berkeley Structural Genomics Center, Lawrence Berkeley National Laboratory.
Stephen Altschul, PhD
Investigator, National Center for Biotechnology Information, National Institutes of Health
Axel Brunger, PhD
Investigator and Professor, Howard Hughes Medical Institute, Department of Molecular and Cellular Physiology, Stanford University
Jack Dixon, PhD
Professor and Chair, Department of Biological Chemistry, University of Michigan Medical School
Tony Hunter, PhD
Professor, Molecular Biology and Virology Laboratory, The Salk Institute
Joseph Schlessinger, PhD
Co-founder of Plexxikon and Professor and Chair, Department of Pharmacology, Yale University of Medical School
Arthur Weiss, MD, PhD
Investigator, Howard Hughes Medical Institute, University of California, San Francisco
"We are very pleased to have recruited these prominent scientific experts to our Scientific Advisory Board. Plexxikon's integrated approach to drug discovery is supported by the breadth of life sciences disciplines represented by our scientific advisors," said Dr. Peter Hirth, CEO of Plexxikon. "With their collective industry and academic expertise, our SAB brings significant value and practical experience to Plexxikon as we build out our Scaffold Discovery FactoryT platform from which multiple drugs for specific targets can be developed."
Plexxikon Profile
Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease. Plexxikon's proprietary Scaffold-Based Drug Discovery™ platform is being applied to build therapeutic franchises in metabolic and cardiovascular disease, inflammation and oncology. This discovery process integrates a number of state-of-the-art technologies, including structural screening as one key component that provides a significant competitive advantage over other drug discovery approaches. To date, the company has discovered a portfolio of clinical and preclinical stage compounds in each of these franchises.
Currently, the company's most advanced program is a PPAR pan-agonist for the treatment of diabetes and related cardiovascular complications, with the lead candidate now in Phase 2 clinical testing in collaboration with Wyeth Pharmaceuticals. Other discovery programs include a dual kinase inhibitor for the treatment of rheumatoid arthritis and other inflammatory diseases and a renin inhibitor for hypertension in collaboration with Servier. Plexxikon is seeking pharmaceutical and biotechnology partners for select collaboration opportunities. For more information, please visit www.plexxikon.com.
2007 | 2006 | 2001 - 2005
Back to Top
|
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
